Pharmaceuticals, Biotechnology and Life Sciences
One of CARsgen Therapeutics’ leading drug candidates, CT053 fully human BCMA (B-Cell Maturation Antigen)-CAR-T cell for the treatment of patients suffering from relapsed/refractory multiple myeloma (rrMM), has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration (FDA).
Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.
It is estimated that there were approximately 92.2
million prevalent cases of uterine fibroids worldwide in females aged
15 years and over, and forecasts that number to increase to 102.7
million prevalent cases by 2026.
Estimation says that in 2017, there were approximately 19,950
incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
forecasts that number to increase to 23,880 incident cases by 2026.
Therapeutics Market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe) is witnessed to
grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”
– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –
ObsEva’s has recently cleared with the U.S. Food and Drug Administration (FDA) several important development issues for its oral oxytocin receptor antagonist nolasiban, which enables it to begin its U.S. Phase 3 clinical trial (IMPLANT 3) in the fourth quarter of this year or early 2020.
NEW YORK & SOMERSET, N.J.–(BUSINESS WIRE)–IVERIC bio, Inc. (NASDAQ: ISEE) and Catalent Biologics, today announced that they have entered into…
Encouraging preliminary safety and clinical activity data confirm miransertib’s potential for treating PS and PROS patients Registrational study, MOSAIC (Miransertib…
Findings will support application for European marketing authorization and augment body of data supporting efficacy and utility of its ready-to-use,…